Stealth BioTherapeutics Corp (NASDAQ:MITO) saw its shares skyrocket Tuesday on quarterly figures.
The clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, reported received gross proceeds of $4.7 million from the registered direct offering of its ADSs.
Net loss was $7.7 million , or $0.01 basic and diluted net loss per ordinary share, for the three months ended March 31, 2021 , as compared to $15.5 million , or $0.04 basic and diluted net loss per ordinary share, for the same period in 2020.
Cash and cash equivalents were $32.1 million at March 31, 2021 , compared to $32.8 million at December 31 , 2020. In May 2021, the Company received an additional commitment of $30.0 million under the Development Funding Agreement with Morningside, payable $8.0 million during the second quarter of 2021 and $22.0 million during the fourth quarter of 2021.
The Company is also eligible to receive an additional $5.0 million upon submission of its Barth NDA, which is currently anticipated during the first half of 2022.
R&D expenses were $6.1 million for the three months ended March 31, 2021 , compared to $9.8 million for the same period in 2020.
The decrease was due to a net decrease of $1.7 million in clinical costs primarily driven by the closeout of the company’s Primary Mitochondrial Myopathy development efforts, a decrease of $1.3 million in employee related costs due to the strategic repositioning in 2020 and a decrease of $1.0 million in manufacturing costs offset in part by a $0.2 million net increase in regulatory costs and a $0.1 million increase in preclinical costs.
MITO shares leaped 24 cents, or 20.2%, to $1.43.